OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis
Xing Wang, Dingke Wen, Qiang He, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 23
Xing Wang, Dingke Wen, Qiang He, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 23
Showing 23 citing articles:
Pharmacological management of migraine: current strategies and future directions
Lanfranco Pellesi, Thien Phu, Anders Hougaard
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 673-683
Open Access | Times Cited: 9
Lanfranco Pellesi, Thien Phu, Anders Hougaard
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 673-683
Open Access | Times Cited: 9
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 8, pp. 815-826
Closed Access | Times Cited: 6
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 8, pp. 815-826
Closed Access | Times Cited: 6
Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Refractory migraine
Г. Р. Табеева, O. V. Kosivtsova, N. A. Kovalchuk, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 2, pp. 76-86
Open Access | Times Cited: 5
Г. Р. Табеева, O. V. Kosivtsova, N. A. Kovalchuk, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 2, pp. 76-86
Open Access | Times Cited: 5
A head‐to‐head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene–related peptide for chronic and episodic migraine
Francesco Saccà, Simone Braca, Mattia Sansone, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 6, pp. 788-794
Open Access | Times Cited: 11
Francesco Saccà, Simone Braca, Mattia Sansone, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 6, pp. 788-794
Open Access | Times Cited: 11
Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
Qi Wang, Jingfang Liu, Hao Sun, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 107-117
Open Access | Times Cited: 11
Qi Wang, Jingfang Liu, Hao Sun, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 107-117
Open Access | Times Cited: 11
Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients
Alessandra Della Vecchia, Ciro De Luca, Lucrezia Becattini, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 677-677
Open Access | Times Cited: 3
Alessandra Della Vecchia, Ciro De Luca, Lucrezia Becattini, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 677-677
Open Access | Times Cited: 3
Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
Hema Mistry, Seyran Naghdi, Anna Brown, et al.
Health Technology Assessment (2024), pp. 1-329
Open Access | Times Cited: 2
Hema Mistry, Seyran Naghdi, Anna Brown, et al.
Health Technology Assessment (2024), pp. 1-329
Open Access | Times Cited: 2
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial
Linus Jönsson, Stephane A. Régnier, Steven Kymes, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 23, Iss. 7, pp. 797-803
Open Access | Times Cited: 3
Linus Jönsson, Stephane A. Régnier, Steven Kymes, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 23, Iss. 7, pp. 797-803
Open Access | Times Cited: 3
An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea
Twan Sia, Taylor Webb, Shufeng Li, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 6, pp. 776-778
Closed Access | Times Cited: 2
Twan Sia, Taylor Webb, Shufeng Li, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 6, pp. 776-778
Closed Access | Times Cited: 2
Scoping Review: The Effects of Interrupted Onabotulinumtoxin A Treatment for Chronic Migraine Prevention During the COVID-19 Pandemic
Qing Ruan, Daniel Pak, Amitabh Gulati, et al.
Journal of Pain Research (2024) Vol. Volume 17, pp. 4163-4176
Open Access
Qing Ruan, Daniel Pak, Amitabh Gulati, et al.
Journal of Pain Research (2024) Vol. Volume 17, pp. 4163-4176
Open Access
Calcitonin Gene-Related Peptide and Adrenomedullin Levels During Ictal and Interictal Periods in Patients With Migraine
Abdurrahman Neyal, Yasemin Ekmekyapar Fırat, Mustafa B Çekmen, et al.
Cureus (2023)
Open Access | Times Cited: 1
Abdurrahman Neyal, Yasemin Ekmekyapar Fırat, Mustafa B Çekmen, et al.
Cureus (2023)
Open Access | Times Cited: 1
Migraine Preventive Treatment Failure: A Cross-Sectional Study in a Tertiary Center in Brazil
Arão Belitardo Oliveira, Eduardo de Almeida Guimarães Nogueira, Mário Fernando Prieto Peres
Deleted Journal (2023) Vol. 14, Iss. 4, pp. 221-229
Open Access | Times Cited: 1
Arão Belitardo Oliveira, Eduardo de Almeida Guimarães Nogueira, Mário Fernando Prieto Peres
Deleted Journal (2023) Vol. 14, Iss. 4, pp. 221-229
Open Access | Times Cited: 1
Hilfestellungen zur wirtschaftlichen Verordnung monoklonaler Antikörper
Jörg Hohmann
NeuroTransmitter (2024) Vol. 35, Iss. 4, pp. 34-37
Closed Access
Jörg Hohmann
NeuroTransmitter (2024) Vol. 35, Iss. 4, pp. 34-37
Closed Access
Ibero-American consensus statement on migraine treatment.
J.M. Láinez, Oscar Enrique Pradilla-Vesga, Pablo Irimia, et al.
Neurology Perspectives (2024), pp. 100182-100182
Open Access
J.M. Láinez, Oscar Enrique Pradilla-Vesga, Pablo Irimia, et al.
Neurology Perspectives (2024), pp. 100182-100182
Open Access
Pharmacotherapy approaches to migraine prevention and treatment
A. R. Sirazutdinova, А. А. Zvegintseva, М. Л. Максимов
Glavvrač (Chief Medical Officer) (2023), Iss. 2, pp. 28-41
Closed Access
A. R. Sirazutdinova, А. А. Zvegintseva, М. Л. Максимов
Glavvrač (Chief Medical Officer) (2023), Iss. 2, pp. 28-41
Closed Access
Anwendung monoklonaler Antikörper zur Migräneprophylaxe in der Praxis
Ruth Ruscheweyh, Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2023) Vol. 25, Iss. 3, pp. 30-39
Closed Access
Ruth Ruscheweyh, Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2023) Vol. 25, Iss. 3, pp. 30-39
Closed Access
Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario
Andrea Zovi, Ruggero Lasala, Francesco Ferrara, et al.
Hospital Pharmacy (2023) Vol. 59, Iss. 2, pp. 165-172
Open Access
Andrea Zovi, Ruggero Lasala, Francesco Ferrara, et al.
Hospital Pharmacy (2023) Vol. 59, Iss. 2, pp. 165-172
Open Access
Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
Yan Tereshko, Simone Dal Bello, Sara Pez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7329-7329
Open Access
Yan Tereshko, Simone Dal Bello, Sara Pez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7329-7329
Open Access
Neues bei Kopfschmerzen 2022–2023
Hans‐Christoph Diener, Dagny Holle, Charly Gaul
Neurologie up2date (2023) Vol. 06, Iss. 04, pp. 345-365
Closed Access
Hans‐Christoph Diener, Dagny Holle, Charly Gaul
Neurologie up2date (2023) Vol. 06, Iss. 04, pp. 345-365
Closed Access
Migraine is a Multifaceted Condition That is More Than Just a Headache: A Review
Amrit Sudershan, Meenakshi Bhagat, Shikha Bharti, et al.
Journal of Chronic Diseases and Management (2023) Vol. 7, Iss. 2, pp. 1-3
Open Access
Amrit Sudershan, Meenakshi Bhagat, Shikha Bharti, et al.
Journal of Chronic Diseases and Management (2023) Vol. 7, Iss. 2, pp. 1-3
Open Access
